Product Images Risedronate Sodium

This is a table showing the mean percentage change in bone mineral density (BMD) for different parts of the body, specifically the lumbar spine, femoral neck, and trochanter, using a placebo and Risedronate Sodium 5 mg, a medication used to treat osteoporosis. No further information is available.*

This text seems to show a table or a graph with different values for the placebo treatment. There are some references to "lumbar", "femoral", "neck" and "trochanter", which suggest that the data is related to bone density or osteoporosis. However, without more context or a clearer image, it is difficult to provide a more specific description.*

This appears to be a table or diagram with two columns, with the left-hand column showing two drug names and strengths (etidronate disodium 400 mg and risedronate sodium 30 mg) separated by a horizontal line. There are no apparent units of measurement or contexts given for these drugs. The right-hand column shows a series of increasing numbers separated by six spaces apiece up to the number 600 at the bottom, labeled "Visit Days". The top of the diagram has a header reading "Percentage (%)" but there is no further indication of what this means or what the numbers in the right-hand column correspond to. It is possible that this is a chart showing some kind of dosing regimen or clinical trial schedule, but without more information it is difficult to say for certain.*

This appears to be a chemical formula and molecular weight information. The formula is likely for a compound with the molecular structure HO-P-C-P-O0Na, and the molecular weight is provided for both the anhydrous form and a hemi-pentahydrate form. No information is given about the compound's properties or potential uses.*

This text provides instructions for taking Risedronate Sodium Tablet, which is typically taken once a month. Patients should select a consistent day and take the tablet with six to eight ounces of plain water on an empty stomach, avoiding eating or drinking anything and lying down for 30 minutes after ingestion. Each tablet contains 150mg of anhydrous risedronate sodium and should be taken as prescribed by a healthcare professional. The medication should be stored in a controlled temperature environment and comes with a medication guide for patients. The manufacturer is Sun Pharmaceutical Industries Limited, and the tablet has an NDC number of 47335-928-60. *

Each tablet of this medication contains 34.428 mg of risedronate sodium hemi pentahydrate, USP which is equivalent to 30 mg of anhydrous risedronate sodium. The medication guide enclosed in the package should be read carefully by patients. The usual dosage is mentioned in the package insert. The tablets are to be stored between 20° to 25°C and in controlled room temperature between 15° to 30°C. The drug is to be kept out of reach of children. The medication is distributed by Sun Pharmaceutical Industries in Cranbury, New Jersey and manufactured in India. Additional information about this medication can be obtained by consulting with the pharmacist.*

This text provides instructions for taking Risedronate Sodium Tablets. The tablet should be taken once a week in the morning with 8 ounces of plain water. It is important to take the tablet on the same day every week. The tablet should be swallowed whole before eating or drinking anything. The patient should not lay down, eat, drink, or take other medications for 30 minutes after taking the tablet. The tablets come in a 4-week supply, and the package contains a medication guide with full prescribing information. The tablets are manufactured by Sun Pharmaceutical Industries Limited and distributed by Sun Pharmaceutical Industries, Inc.*

This is a package insert for Risedronate Sodium Tablets, USP, a medication used to treat osteoporosis. Each tablet contains 5.738 mg of risedronate sodium hemi pentahydrate, which is equivalent to 5 mg of anhydrous risedronate sodium. The usual dosage and prescribing information can be found on the package outsert, and it should only be taken as directed by a healthcare professional. Patients should also read the enclosed Medication Guide before taking this medication. It should be stored at a controlled room temperature between 20° to 25°C and kept out of reach of children. The NDC number is 47335-666-83, and this medication is distributed by Sun Pharmaceutical Industries, Inc. and manufactured by Sun Pharmaceutical Industries Ltd. in India.*

This is a set of instructions for taking Risedronate Sodium Tablets. The user should choose any two consecutive days to take one tablet on each. On the first day, you should swallow one tablet with plain water before eating or drinking anything else. The user should avoid lying down, eating, drinking or taking other medications for 30 minutes after taking the tablet. The same process should be repeated on the second day. The pack contains two tablets for one month. The medication is only available through prescription. The medication guide included should be read thoroughly before using the tablets.*